A study of 2,282 adults aged 60 and older found anemia was associated with higher Alzheimer’s disease blood biomarkers and a 66% higher chance of developing dementia. The highest risk was seen in participants with both anemia and higher biomarker levels.
CervoMed presents new MRI data showing neflamapimod may reduce basal forebrain atrophy in dementia with Lewy bodies and finalizes Phase 3 trial design. The drug has also been selected for a UK-funded ALS platform trial, with first dosing expected by end of 2026.
uniQure disclosed the FDA will not accept Phase I/II data alone for AMT-130 approval, causing shares to drop 49%. The company held regulatory meetings and reported $622.5 million in cash while investors face an April 13 class action deadline.
Coya Therapeutics detailed plans for a Phase 2 trial of combination immunotherapy targeting neuroinflammation in ALS, following a four-patient study showing biomarker improvements and reported slowing of disease progression.
Researchers at DZNE and the University of Tübingen have identified neurofilament light chain (NfL) as a blood biomarker detectable across animal species, with levels increasing with age and predicting lifespan in mice.
Novartis debuted its "Relax, it's a blood test" prostate cancer awareness initiative at Super Bowl LX with an experiential booth and commercial featuring NFL tight ends, ranking seventh among all ads.
